Processa Pharmaceuticals (PCSA) Financials

$2.16

$0.10 (4.85%)

As on 08-Sep-2026 16:26EDT

Market cap

$6 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

3.2

P/B Ratio

2.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.00	0.00	0.00	0.00	0.87	0.88
Gross Profit	0.00	0.00	0.00	0.00	-0.87	-0.88
Operating Expenses	12.86	13.99	12.05	11.46	19.38	12.13
Operating Profit (EBIT)	-12.86	-13.99	-12.05	-11.46	-20.26	-12.13
Other Income	--	--	--	--	--	--
Profit before Tax	-13.44	-13.56	-11.85	-11.12	-27.42	-11.96
Provision for Tax	--	--	--	0.00	27.42	-0.53
Profit after Tax (Net Income)	-13.44	-13.56	-11.85	-11.12	-27.42	-11.43
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	-11.43

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-0.32	5.58	1.70	4.99	7.47	25.49
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	0.00	0.07	0.15	0.01
Current Liabilities	2.39	2.24	1.53	0.73	1.00	0.97
Total Liabilities	4.46	7.81	3.23	5.79	8.62	26.46

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.00	2.14	1.36	0.15	0.23	8.14
Current Assets	2.07	5.67	1.87	5.63	8.39	18.33
Total Assets	4.14	7.81	3.23	5.79	8.62	26.46
Total Debt*	--	--	0.07	0.15	0.23	0.08
Net Current Assets	--	3.43	0.34	4.90	7.39	17.36

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-11.39	-11.25	-8.06	-9.61	-8.72
Cash Flow from Investing Activities	--	-0.85	0.00	0.00	--	--
Cash from Financing Activities	--	16.58	7.73	6.27	-0.39	9.80
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-5.59	-5.27	-80.12	-216.37	-854.34	-363.93
Cash EPS ($)	--	-5.27	-80.12	-212.54	-829.77	-338.74
Adjusted Book Value ($)	--	2.17	11.47	97.07	232.73	811.63
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-4.43	-76.03	-156.87	-299.23	-277.62
Free Cash Flow per Share ($)	--	-4.43	-76.05	-156.93	-299.23	-277.62

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-369.24	-343.01	-173.23	-164.89	-46.80
ROE (%)	--	-372.97	-354.51	-178.52	-166.43	-47.20
ROA (%)	-186.74	-245.66	-262.87	-154.40	-156.34	-44.23
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-4.30	-14.46	-6.55	59.45	-137.09	23.57
Net Profit Growth (%)	-4.32	-14.46	-6.55	59.45	-139.98	39.98
EPS Growth (%)	90.37	0.93	0.63	0.75	-1.35	0.68
Book Value Growth (%)	-101.18	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	3.17	-0.55	-0.01	0.00	0.00	-0.01
Price / Book Value	2.81	1.33	0.08	0.00	0.00	0.01
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.14	-0.14	0.08	0.41	0.23	1.51
Close Price ($)	1.92	2.88	22.10	167.50	550.00	2,450.00
High Price ($)	83.75	83.75	3,570.00	725.00	2,630.00	7,119.95
Low Price ($)	1.76	2.75	20.30	90.00	505.00	1,927.25
Market Cap ($ Cr)	5.75	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	0.04	0.03	0.03	0.00
Short term debt to equity ratio	--	--	0.04	0.02	0.01	0.00
Current Ratio	0.87	2.54	1.22	7.71	8.40	18.87
Quick Ratio	0.87	--	--	--	--	--
Interest Coverage	-6,708.03	--	--	--	-270.99	-31,952.93

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	293,910.37	278,490.75	525,799.59	114.18	112.58
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.